Clinical trialNCT03364231CompletedPhase 2Interventional

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

SponsorTG Therapeutics, Inc.Enrollment21Marginal Zone LymphomaNon Follicular Indolent Non-Hodgkin LymphomaWaldenstrom Macroglobulinemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Bruce Cheson, MD
Lombardi Comprehensive Cancer Center
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Tg Therapeutics Investigational Trial Site
Washington D.C., District of Columbia, United States
Tg Therapeutics Investigational Trial Site
Boston, Massachusetts, United States
Tg Therapeutics Investigational Trial Site
Hackensack, New Jersey, United States
Tg Therapeutics Investigational Trial Site
New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Umbralisib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2017
Primary completion: 15 Feb 2022
Completion: 15 Feb 2022
Last update posted: 23 Jun 2023
Registered enrollment: 21
Registry id: NCT03364231

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.